Navigation Links
AEterna Zentaris Announces Appointment of New Board Member
Date:12/9/2009

.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.

SOURCE AETERNA ZENTARIS INC.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
2. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
4. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
5. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
6. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
7. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
8. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
9. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
10. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
11. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2015)... ... July 26, 2015 , ... Maine Standards ... verification / linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and ... prepared using the CLSI recommended “equal delta” method for linearity testing and is ...
(Date:7/24/2015)... , July 24, 2015 Ryan & ... filed in United States District Court for the Northern District ... persons or entities that purchased the common stock of Avalanche ... between July 31, 2014 and June 15, 2015, inclusive (the ... September 8, 2015, move the Court for appointment as a ...
(Date:7/24/2015)... July 24, 2015 Equity Research ... BioPharma Inc. (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. ... ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ), and ... report on PDL BioPharma can be accessed at ... Composite ended at 5,146.41, down 0.49%, the Dow Jones ...
(Date:7/24/2015)... 2015 Orexigen Therapeutics, Inc. (Nasdaq: OREX ... second quarter 2015 on Thursday, August 6 before the ... business update and discuss the financial results in a ... Time (5:00 a.m. Pacific Time). The live ... 447-0521 (domestic) or (847) 413-3238 (international), participant code 40327229. ...
Breaking Biology Technology:Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... antibodies that react to the sample. The test result can be ... does or does not appear depending on the sample ... It is also possible to print instructional images or text, for ... be used to test quickly and easily for the presence of ...
... Oct. 6 InterMune, Inc. (Nasdaq: ITMN ... and commercialization rights to danoprevir (also known as RG7227 ... Roche Ltd. for $175 million in cash.  In connection ... Roche entered into in October 2006 has been terminated. ...
... That Produces Isobutene From... -- EVRY, France, October 6, 2010 ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:VTT printed hemoglobin test on paper 2InterMune Sells Danoprevir Rights to Roche for $175 Million 2InterMune Sells Danoprevir Rights to Roche for $175 Million 3InterMune Sells Danoprevir Rights to Roche for $175 Million 4Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose 2Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose 3Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose 4Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose 5Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose 6Global Bioenergies Succeeds in Creating a Bacterial Prototype That Produces Isobutene From Glucose 7
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
(Date:7/8/2015)... , July 8, 2015 The ... as this summer,s must have products such as wearables, smart ... as popularity for biometrics based devices continues to rapidly grow.  ... Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: GOOG ... FIT ), GoPro, Inc. (NASDAQ: GPRO ) and ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... the major regulator of virtually all metabolic activities ... vesicular transport and programmed cell death. Dysregulation of ... diseases such as cancer and neurodegenerative disorders. In ... proved pivotal for understanding and manipulating cellular behaviour ...
... previous research suggests that prominent claims of sex differences ... according to an article in the August 22/29 issue ... many common diseases, published research has often considered that ... men vs. women. Many diseases or traits with strong ...
... Genetic testing can be used to help personalize the ... research published in the September 1, 2007, issue of ... of Hematology. This result represents one of the first ... personal medical care. Because individuals metabolize drugs differently, ...
Cached Biology News:All eukaryotic kinases share 1 common set of substrates 2Claims of sex-related differences in genetic association studies often not properly validated 2Genetics determine optimal drug dose of common anticoagulant 2
kismet (dK-20)...
... Thermo Hybaid's unique Electro-4 design allows ... the Electro-4 it is possible to run ... tank, by stacking up to four,horizontal gels. ... adjustable according to the number of gels ...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: